Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food and Calcium on Lusutrombopag PK
NCT03897413Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lusutrombopag in Thrombocytopenia (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Time to Maximum Observed Plasma Concentration at 96 hours and 4 more. Started Nov 2009; status: completed.
02
Drugs
lusutrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT03897413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897413.